Early Safety and Efficacy of a Phase 1/2 Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with Advanced SquamousCell Carcinoma of the Head and Neck. See PDF here.
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Early Safety and Efficacy of a Phase 1/2 Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with Advanced SquamousCell Carcinoma of the Head and Neck. See PDF here.